Drug discovery and development for acute heart failure drugs: Are expectations too high?

International Journal of Cardiology

Volumn 172, Issue 1, 2014, Pages 11-13

  Pollesello, Piero ^a  

^a ORION CORPORATION   (Finland)

Author keywords

Acute heart failure; Clinical trials; Drug discovery and development; Levosimendan; Omecamtiv mecarbil

Indexed keywords

CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; OMECAMTIV MECARBIL; PYRIDAZINE DERIVATIVE; SIMENDAN; UREA;

ACUTE DISEASE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; HEART FAILURE; HUMAN;

ACUTE DISEASE; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES; UREA;

EID: 84894083362     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.136     Document Type: Editorial

References (25)

1. M.A. Konstam RELAX-AHF: rising from the doldrums in acute heart failure Lancet 381 2013 5 6
2. R.J. Mentz, G.M. Felker, and T. Ahmad et al. Learning from recent trials and shaping the future of acute heart failure trials Am Heart J 166 4 2013 629 635
3. M.M. Givertz, J.R. Teerlink, and N.M. Albert et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research J Card Fail 19 2013 371 389
4. M.S. Nieminen, D. Brusaert, and K. Dickstein et al. Tavazzi L; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur Heart J 27 2006 2725 2736
5. K. Dickstein, A. Cohen-Solal, and G. Filippatos et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 2008 933 989
6. J.J. McMurray, S. Adamopoulos, and S.D. Anker et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 14 8 Aug 2012 803 869
7. A.P. Davie, C.M. Francis, L. Caruana, G.R. Sutherland, and J.J. McMurray Assessing diagnosis in heart failure: which features are any use? QJM 90 1997 335 339
8. S. Price, and U. Shadama Part XII medical therapy for acute heart failure - inotropes pressors and vasodilators T.A. McDonagh, R.S. Gardner, A.L. Clark, H. Darfie, Oxford textbook of heart failure 2011 Oxford University Press UK
9. J. Pöss, A. Link, and M. Böhm Pharmacological treatment of acute heart failure: current treatment and new targets Clin Pharmacol Ther 94 2013 499 508
10. L.E. Rohde, E.G. Bertoldi, L. Goldraich, and C.A. Polanczyk Cost-effectiveness of heart failure therapies Nat Rev Cardiol 10 2013 338 354
11. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev 3 2004 711 715
12. K. Kaitin, and J. DiMasi Pharmaceutical innovation in the 21st century: new drug approval in the first decade, 2000-2009 Clin Pharmacol Ther 89 2011 183 188
13. Mathon J. Cardiovascular Trials Initiated by Disease and Company. In PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 (Mathieu MP, Ed., PAREXEL International Corporation, USA) pp.99-100
14. P. Pollesello, Z. Papp, and M.S. Nieminen Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed? Int J Cardiol. 168 2013 4798 4799
15. M. Packer, W. Colucci, and L. Fisher et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure JAHF 1 2013 103 111
16. J.R. Teerlink, G. Cotter, and B.A. Davison et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
17. B.M. Massie Clinical trials in heart failure: can we expect the results to be replicated in clinical practice? J Card Fail 4 1998 243 247
18. E.S. Nakou, and P.E. Vardas New therapeutic options in heart failure. What's on the horizon? An overview Int J Cardiol 170 2013 95 106
19. H. Haikala, and P. Pollesello Calcium sensitivity enhancers IDrugs 3 2000 1199 1205
20. F.I. Malik, J.J. Hartman, and K.A. Elias et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure Science 331 2011 1439 1443
21. ESC Congress 365. ATOMIC-AHF: Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: results from ATOMIC-AHF Available at http://congress365.escardio.org/Search-Results?presentation= C365PRESENTATION90685&doc [accessed on Sept 3, 2013]
22. J.G.F. Cleland, J.R. Teerlink, and R. Senior et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 2011 676 683
23. M.R. Bristow Pharmacogenetic targeting of drugs for heart failure Pharmacol Ther 134 2012 107 115
24. D. Shaywitz Strategy: why big pharmas do what they do - and how Silicon Valley might help them think differently http://www.forbes.com/sites/ davidshaywitz/2013/03/23/strategy-why-big-pharmas-do-what-they-do-and-how- silicon-valley-might-help-them-think-differently/ Dec 30, 2013 accessed Dec 30, 2013
25. S.P. Collins, C.J. Lindsell, and P.S. Pang et al. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial Am Heart J 164 2012 138 145